Related Experiment Video
Updated: Jul 7, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Review article: novel therapeutic options for chronic hepatitis C
E Cholongitas1, G V Papatheodoridis
1Department of Internal Medicine, General Hospital of Sitia, Sitia, Greece. gepapath@med.uoa.gr
Background:
The efficacy of treatment against hepatitis C virus has improved, but it is still far from ideal. Thus, new antihepatitis C virus therapies are required.
Aim:
To evaluate the data on antihepatitis C virus approaches beyond the current standard combination of pegylated interferon-alpha and ribavirin.
Method:
We reviewed the available literature regarding novel antihepatitis C virus options, given alone or in combination with existing agents.
Results:
New interferons and ribavirin alternatives have been tried aiming to improve the efficacy and the safety/tolerability profile of standard agents. The hepatitis C virus polymerase and NS3/4A protease have been rather popular targets for new antihepatitis C virus agents. The combination of such inhibitors with pegylated interferon-alpha and ribavirin seems to act synergistically and to prevent viral resistance, compared to monotherapies. Several novel immunomodulators are currently evaluated and may be useful in combination therapies. Alternative strategies (inhibition of hepatitis C virus protein translation, assembly/release or binding) or agents with different modes of action (statins, S-adenosylmethionine and herbs) need further evaluation.
Conclusions:
Many novel promising antihepatitis C virus agents are being developed, offering hope for future therapies that may target multiple points of the viral life cycle and/or host immune response. Newer approaches should ideally provide safe, effective and more tolerable therapy to all chronic hepatitis C virus patients.
Related Concept Videos
Hepatitis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inhibitors of Viral Protein Synthesis
Chronic Pancreatitis II: Collaborative Care
Assessment:
Viral Hepatitis I: Introduction
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
